 |
|
Age-Related Macular Degeneration
Treating the Whole Patient
Arch Ophthalmol. 2004;122:648-649.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Age-related macular degeneration (AMD), the leading cause of legal blindness in persons 65 years or older in the United States, affects more than 10 million Americans and perhaps an equal number of persons in Western Europe.1 As the baby boomers—some already in their 50s—get older, these numbers will only increase. The Beaver Dam Eye Study, Beaver Dam, Wis, found the prevalence of advanced AMD in persons 75 years and older to be 7.8%.2 In both Australia and the United Kingdom, the prevalence of blindness among those older than 85 years who have AMD has been reported to be 18.5%, and in the United Kingdom AMD is responsible for 95% of blindness in this age group.3-4 In Denmark, the 1-year incidence of legal blindness after the age of 80 years is 212 cases per 1 million; AMD accounts for 60% of all blind persons aged 60 to 80 years.5
Regrettably and . . . [Full Text of this Article]
William Tasman, MD;
Barry Rovner, MD
Philadelphia, Pa
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Power of Partnering
Phillips
Arch Ophthalmol 2005;123:1618-1618.
FULL TEXT
Ophthalmologists' Referrals Improve the Lives of Visually Impaired Patients
Greenblatt
Arch Ophthalmol 2005;123:872-873.
FULL TEXT
Community-Based Vision-Rehabilitation Services Provide Help and Hope
Ekin
Arch Ophthalmol 2005;123:285-285.
FULL TEXT
Promoting Social Science Collaboration With Ophthalmology
Kirchner
Arch Ophthalmol 2005;123:285-286.
FULL TEXT
|
